Zepbound and Tirzepatide Explained: Brand, Drug Name, Indications

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Zepbound and tirzepatide are two names that refer to the same active ingredient — but not in the same way, and the difference matters clinically and commercially. Tirzepatide is the generic (nonproprietary) drug name. Zepbound is Eli Lilly's brand name for tirzepatide when it is prescribed for chronic weight management. The same molecule is also sold as Mounjaro, which is Eli Lilly's brand name for tirzepatide when it is prescribed for type 2 diabetes. This article explains the relationship, why it exists, and what it means for coverage, cost, and care decisions.

What Zepbound and tirzepatide are

Tirzepatide is a GIP/GLP-1 dual agonist — a single peptide that engages both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual-receptor engagement is the mechanical feature that distinguishes tirzepatide from GLP-1-selective compounds like semaglutide. Zepbound is the branded product name for tirzepatide marketed for chronic weight management; it was FDA-approved in November 2023 for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition. In December 2024, Zepbound received an additional FDA approval for obstructive sleep apnea in adults with obesity — the first medication approved specifically for that indication.

Why one molecule has two brand names

Eli Lilly launched tirzepatide as Mounjaro in 2022, FDA-approved for type 2 diabetes. When the company pursued chronic weight management as a separate indication, FDA approved the same active ingredient under a separate brand — Zepbound — with its own product label, dosing titration schedule, and insurance coverage logic. The practical reason for two brands: insurance coverage, prior authorization criteria, and patient-assistance programs operate at the product-label level, not the molecule level. Many plans that cover Mounjaro for type 2 diabetes do not cover Zepbound for weight management (or vice versa).

How the medication works

Tirzepatide engages the GIP and GLP-1 receptors in the pancreas, hypothalamus, and gastrointestinal tract — slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and increasing satiety signaling. The dual-receptor design is hypothesized to contribute to the magnitude of weight reduction observed in the SURMOUNT clinical trial program (as published in the New England Journal of Medicine, 2022–2024). FDA-approved weight-management dosing begins at a low starting dose and titrates upward over several weeks per the approved label — your prescribing provider will cover the specifics.

What Zepbound is approved for

Zepbound is FDA-approved for: (1) chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity (approved November 2023), and (2) obstructive sleep apnea in adults with obesity (approved December 2024). The sleep apnea approval was based on the SURMOUNT-OSA trial, which evaluated tirzepatide in adults with moderate-to-severe OSA and obesity and showed reductions in apnea-hypopnea index. Mounjaro (the diabetes brand of tirzepatide) remains separately approved for type 2 diabetes.

Cost and access

Zepbound list price is approximately $1,059 per month at U.S. list price as of April 2026 (Eli Lilly published pricing). Out-of-pocket cost depends on insurance coverage, the FDA indication for which the prescription is written, manufacturer savings card eligibility, and whether a compounded alternative is available through a licensed compounding pharmacy pathway. The FDA's 2024–2025 resolution of the tirzepatide shortage narrowed the compounding-pharmacy window, though legitimately compounded tirzepatide remains available through 503A pharmacy pathways where clinically justified. See Zepbound cost in 2026 and Mounjaro cost in 2026 for the current savings-program landscape.

The genetic variable

Whether a clinician prescribes Zepbound, Mounjaro, or any other tirzepatide-based protocol, the upstream genetic architecture is the same. Variants in FTO (fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene — one of the two receptors tirzepatide engages), and MC4R (a melanocortin receptor gene central to energy balance) shape the baseline appetite regulation, satiety signaling, and energy-balance biology on which the compound acts. These variants are pathway-level; they do not predict response to any one compound, but they do map the metabolic terrain a clinician is working with.

PlexusDx offers tirzepatide through its Weight Management Protocols — available as Tirzepatide Injection and Tirzepatide Oral formats. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: Online Zepbound, Oral Zepbound, Retatrutide vs Zepbound, Trulicity vs Zepbound.

Disclaimer: This article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols — this article covers the mechanism, FDA-approved indications, and genetic context that informs any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology that shapes every tirzepatide decision. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols to see how PlexusDx pairs the protocol with the upstream genetic context.

Frequently Asked Questions

Is Zepbound the same as tirzepatide?

Yes — Zepbound is Eli Lilly's brand name for tirzepatide when prescribed for chronic weight management or obstructive sleep apnea. The active ingredient is identical to Mounjaro (the diabetes-labeled brand). Because insurance coverage and prior authorization operate at the product-label level, the two brands are handled separately by pharmacies and plans.

Is Zepbound the same as Mounjaro?

Same molecule, different brand. Mounjaro is tirzepatide labeled for type 2 diabetes; Zepbound is tirzepatide labeled for chronic weight management and, as of December 2024, obstructive sleep apnea. FDA maintains separate product labels. Your provider prescribes the brand that matches the indication, which affects insurance coverage and copay.

What is Zepbound FDA-approved for?

Zepbound is FDA-approved for two indications: chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with a weight-related condition (November 2023), and obstructive sleep apnea in adults with obesity (December 2024, based on SURMOUNT-OSA). Mounjaro is separately approved for type 2 diabetes.

Does genetic testing predict my Zepbound response?

No. The Precision Peptide Genetic Test does not predict response to Zepbound, tirzepatide, or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and related genes that shape baseline GLP-1 and energy-balance biology — the upstream variable that applies to any tirzepatide protocol regardless of brand.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education